Intraosseous Infusion Devices Market | Revenue, Sales, Latest Trends and Forecast

Market Summary and Growth Forecast

The global Intraosseous Infusion Devices Market is estimated at $560 million in 2026 and is expected to reach $980 million by 2035, growing at a CAGR of 6.4%.

Intraosseous infusion devices provide temporary vascular access through the medullary cavity of a bone. They are used when conventional intravenous access cannot be established quickly or reliably. Medications, fluids, blood products and emergency drugs can then enter systemic circulation through the bone marrow’s vascular network.

The market includes powered and manually operated insertion systems, intraosseous needles, spring-loaded devices, stabilization products, extension sets and integrated procedure trays. It excludes standard intravenous catheters, infusion pumps, bone-biopsy systems and investigational implantable access ports.

The business relevance of the Intraosseous Infusion Devices Market comes from one basic clinical problem: vascular access often becomes harder when the patient is at greatest risk. Severe shock, cardiac arrest, major trauma, burns, obesity, dehydration and collapsed peripheral veins can make conventional IV placement slow or unsuccessful. IO access acts as a bridge until stable peripheral or central access is established. It is used in adult, pediatric and neonatal emergencies.

Global Market Forecast

These figures are original analyst estimates. They are built from expected disposable utilization, installed driver systems, replacement demand, hospital and EMS purchasing patterns, supplier portfolio activity and geographic adoption.

Why the Market Will Continue to Expand

Emergency vascular access remains clinically necessary

Updated resuscitation guidance creates a more precise role for IO access rather than removing it from emergency care. The American Heart Association’s 2025 adult cardiac-arrest guidance recommends attempting IV access first. It states that IO access remains reasonable when IV access is unsuccessful or not feasible. This protects IO demand as an essential backup route, although it may limit aggressive positioning as the default first-line method in every adult cardiac arrest.

European guidance also continues to recognize intraosseous access as an alternative method for emergency administration of medications and fluids. Local implementation will still depend on national protocols, responder training and institutional practice.

The market is shifting from individual devices to complete access systems

Hospitals and emergency responders increasingly want a standardized system rather than a standalone needle or driver. Buyers now evaluate the insertion device, needle range, extension set, stabilization dressing, sharps protection, battery status and training package together.

This favors suppliers capable of building complete platforms. Teleflex, for example, offers powered IO systems, needle sets, stabilization products and sternal access devices. Its emergency medicine portfolio serves hospital, EMS and military users.

Difficult vascular access is receiving more attention

Hospitals are placing greater emphasis on first-attempt access success, treatment delays and procedural standardization. IO devices benefit when difficult vascular access protocols clearly define how many IV attempts should be made before an alternative route is used.

The opportunity goes beyond cardiac arrest. Severe sepsis, hemorrhagic shock, major trauma, pediatric emergencies, perioperative complications and time-critical medication delivery can all support use. This broadens the addressable clinical base while keeping IO positioned as a temporary access method.

Use case: A paramedic treating a patient in profound shock may be unable to locate a usable peripheral vein. A powered or manual IO device can establish access rapidly, allowing fluids and emergency medication to be administered while the patient is transported.

Device design is improving availability at the point of care

A recurring challenge is not only whether an IO device works. It is whether the complete system is accessible when the emergency occurs. Teleflex reported that its clinician research found cases where hospital staff could not readily access an IO device during time-critical difficult-access situations. Its response was a compact sterile tray that can be stored in code carts and procedure areas.

This creates demand for single-use systems in operating rooms, emergency departments, critical-care units and other sterile environments. It also supports higher revenue per procedure than a basic needle-only purchase.

Production quality and sterile supply are becoming more important

The manufacturing ecosystem combines precision metal cannulas, polymer hubs, battery or mechanical driver assemblies, securement components and sterile packaging. Needle geometry must support cortical penetration without compromising control. At the same time, manufacturers must manage sterilization validation, packaging integrity, shelf life and reliable device performance after long periods of storage.

Product reliability directly affects purchasing decisions. Emergency devices may remain unused for months and then be required immediately. Battery condition, sterility and component availability therefore matter as much as insertion speed.

Regulatory compliance creates a moderate entry barrier

In the United States, dedicated IO systems are generally regulated as medical devices and commonly follow the FDA’s 510(k) pathway. An updated EZ-IO system received a substantially equivalent decision in July 2023 under FDA submission K231924.

Manufacturers also need quality-management systems, biocompatibility evidence, sterilization data, human-factors validation and post-market surveillance. European commercialization has become more demanding under the Medical Device Regulation. Smaller suppliers may have clinically workable designs but still face delays in documentation, distributor qualification and regulatory maintenance.

Key Consumers and Clients

The main customers are:

• Hospitals and health systems, particularly emergency departments, trauma centers, intensive-care units, operating rooms and pediatric departments.
• Emergency medical service providers, including ambulance operators, paramedic units, fire departments and public emergency-response agencies.
• Military and defense medical organizations, especially combat-medicine, field-hospital and tactical-response units.
• Air ambulance and medical evacuation providers, where speed, compact storage and equipment reliability matter.
• Government healthcare procurement agencies, public hospitals and centralized emergency-equipment buyers.
• Medical distributors and group purchasing organizations, which influence product standardization and contract access.
• Training institutions, simulation centers and emergency-medicine education providers.

Large hospital systems usually focus on clinical evidence, compatibility, standardization and staff training. EMS buyers place more weight on ruggedness, storage, speed and battery readiness. Military users also value devices that remain functional without dependable electricity.

Market Segmentation and Forecast Scope

The Intraosseous Infusion Devices Market is best segmented by product type, application, end user and region. Each dimension answers a different commercial question. Product segmentation shows where revenue is generated. Application analysis explains why the device is used. End-user segmentation identifies who controls purchasing. Regional analysis shows where adoption and pricing differ.

The following shares are modeled 2026 estimates. Only selected shares are disclosed. Remaining subsegment values are retained within the detailed forecast model.

By Product Type

Intraosseous Needle Sets and Cannulas

This category includes sterile needles sold individually or with basic access components. Multiple lengths are needed to accommodate neonates, children, adults, patients with higher body mass and different insertion sites.

Needles generate recurring revenue because they are single-use products. They are also closely linked to the installed base of compatible reusable drivers.

Needle sets and cannula-led kits are estimated to represent approximately 58% of global revenue in 2026. Their revenue share is lower than their unit share because reusable drivers and integrated trays have higher selling prices.

Powered Insertion Systems

Powered systems use a battery-operated driver to advance the IO needle through the bone cortex. The category includes reusable powered drivers and newer single-use powered formats.

Powered systems remain strategically important because they support standardized insertion and can be deployed across multiple patient groups. Competition is moving toward battery visibility, ergonomic control, rechargeable designs and device readiness.

Manual and Spring-Loaded Devices

Manual systems use rotational hand force, repeated trigger activation or spring-assisted insertion. They avoid dependence on electric power and may offer lower acquisition costs.

This category has strong relevance in military medicine, disaster response, rural EMS and markets where capital budgets are constrained. SAM Medical, for example, offers a manually operated driver that creates rotational needle movement through repeated trigger actuation.

Procedure Trays and Accessory Systems

This segment covers sterile procedure trays, securement dressings, extension sets, preparation materials and sharps-management components sold as integrated configurations.

Procedure trays are expected to record the fastest product-level growth at an estimated 8.8% CAGR from 2026 to 2035. They address missing-component risk and reduce the time clinicians spend assembling supplies during an emergency.

For market modeling, revenues are assigned according to the primary invoiced product. A complete procedure tray is therefore counted under procedure trays rather than dividing its value across needles, drivers and accessories. This prevents double counting.

By Application

Emergency and Difficult Vascular Access

This includes patients requiring urgent medication or fluid delivery when peripheral IV access is delayed, difficult or unavailable. It covers emergency departments, intensive-care situations and urgent in-hospital procedures.

This is the broadest application group and is estimated to account for approximately 39% of revenue in 2026.

Trauma and Hemorrhagic Shock

Major trauma can cause vascular collapse, low blood pressure and poor peripheral access. IO devices may be carried by ambulance crews, trauma teams, military medics and air-evacuation units for rapid resuscitation.

Demand in this category is influenced by trauma protocols, pre-hospital care capabilities and the availability of trained personnel.

Cardiac Arrest and Resuscitation

IO access is used when emergency drugs must be administered and IV placement is unsuccessful or impractical. Cardiac-arrest utilization is estimated to contribute approximately 25% of market revenue in 2026.

Growth in this segment will be steady rather than aggressive. New evidence and guidelines favor IV-first strategies when feasible. That said, IO remains embedded in resuscitation algorithms as an alternative access route.

Pediatric and Neonatal Emergencies

Children and neonates can present serious vascular-access challenges because their veins are smaller and harder to access during shock or cardiac arrest. Pediatric IO systems require appropriate needle lengths, anatomical guidance and regular clinician training.

Unit demand is lower than in adult emergency care. The strategic value is still high because pediatric resuscitation programs often require IO capability as part of preparedness.

Military, Tactical and Disaster Medicine

This segment covers combat casualties, mass-casualty events, remote rescue, disaster response and austere-care environments.

Manual and compact systems perform well here. Devices must withstand storage, transport and rough handling. Battery-independent operation can be a real advantage.

By End User

Hospitals and Trauma Centers

Hospitals represent the largest end-user category, with an estimated 51% revenue share in 2026. The category includes emergency departments, intensive-care units, operating rooms, pediatric departments and specialist vascular-access teams.

Hospital revenue per account can be higher because institutions purchase drivers, disposable needles, trays, training products and replacement accessories. Conversion can be slow, however. Clinical committees and procurement teams may require trials, training assessments and contract negotiations before replacing an established platform.

EMS, Ambulance and Fire-Rescue Services

EMS and public emergency-response organizations are estimated to account for approximately 31% of market revenue in 2026.

These buyers need compact systems that can be stored in ambulances and emergency bags. Ease of training is crucial because actual IO use may be infrequent for an individual responder. Products must remain ready even after long storage periods.

Military and Defense Medical Units

Military purchasers evaluate performance in field environments, device weight, storage life, manual backup capability and speed of deployment. Procurement may occur through multiyear government contracts or specialist tactical-medical distributors.

Air Ambulance, Remote Care and Other Users

This includes medical evacuation operators, wilderness rescue teams, offshore medical services, urgent-care facilities and specialized transport providers.

The segment is smaller but commercially attractive for battery-independent systems and compact procedure kits.

By Region

North America

North America is estimated to hold approximately 42% of global revenue in 2026. The United States supports a large installed base across hospitals, EMS systems, military medicine and advanced resuscitation programs.

The region also has strong supplier activity. Teleflex, BD and SAM Medical maintain active commercial IO portfolios in the United States. Recent product launches show that suppliers still see meaningful room for platform conversion and product differentiation.

Europe

European demand is supported by established ambulance systems, trauma networks and resuscitation training. Adoption differs by country because purchasing structures and clinical protocols are not uniform.

Growth will come from replacing older systems, expanding adult IO training and increasing the use of integrated kits. MDR compliance may favor established manufacturers with stronger regulatory resources.

Asia Pacific

Asia Pacific is expected to be the fastest-growing major region at an estimated 7.7% CAGR from 2026 to 2035.

China, Japan, South Korea, Australia and selected Southeast Asian markets offer the strongest commercial potential. Growth depends on emergency-care infrastructure, hospital purchasing budgets, clinician training and local product registration.

Latin America, Middle East and Africa

LAMEA remains an uneven market. Large private hospitals, military organizations and leading urban trauma centers use advanced IO systems. Many public institutions still face procurement and training constraints.

Manual and spring-loaded devices can gain traction where maintaining powered equipment is difficult. Distributor reach and participation in government tenders will remain central to market entry.

Across the Intraosseous Infusion Devices Market, consumable revenue will grow faster than the installed driver base. As more hospitals and EMS networks standardize platforms, recurring needles, securement products and complete procedure kits will become the core revenue engine.

Market Trends and Innovation Landscape

Innovation in the Intraosseous Infusion Devices Market is practical rather than digital. Suppliers are focused on insertion control, needle safety, sterility, battery reliability, body-size coverage and faster access to complete procedural supplies.

AI integration isn’t a meaningful product-level theme at present. IO placement remains a hands-on emergency procedure. Digital tools may support training, inventory management or competency tracking, but they are not yet central to the device itself.

Ready-to-Use Sterile Procedure Systems

The industry is moving from separate components toward packaged procedural solutions. This responds to a simple operational problem: a device offers little value if the correct needle, extension set or stabilizer cannot be found when the patient deteriorates.

In May 2024, Teleflex launched a sterile, single-use EZ-IO procedure tray. It combines a battery-powered driver, selected needle length, saline syringe, skin-preparation applicator, stabilizer, extension set, sharps container and quick-reference instructions. The tray can be used in sterile fields and stored in hospital code carts.

This format is likely to expand beyond operating rooms. Emergency departments and critical-care units may adopt similar kits to reduce setup steps and inventory gaps.

Rechargeable Drivers and Visible Battery Status

Reliability is becoming a clearer competitive differentiator. Traditional reusable powered drivers may remain in storage for long periods. A clinician therefore needs immediate confirmation that the device is functional.

In October 2024, BD launched an enhanced IO platform with a rechargeable powered driver and a multi-light battery indicator. The platform also includes manual insertion options, five needle lengths and a securement system designed for different anatomical contours.

This raises the competitive bar. Future powered systems will increasingly be judged on battery visibility, charge retention and ease of readiness checks rather than motor performance alone.

Passive Needle Safety

Needlestick prevention is moving closer to the center of product design. Emergency procedures happen in crowded and high-pressure environments. Exposed stylets can create risk immediately after insertion.

The enhanced BD system incorporates passive needle-tip protection intended to activate as the stylet is removed. This reduces dependence on a separate manual safety step.

Other manufacturers may respond with redesigned stylets, integrated disposal features and more complete sharps-management components.

Improved Stabilization and Infusion Connectivity

Establishing access is only the first step. The cannula must remain secure while fluids and medications are delivered. Poor stabilization can increase the risk of movement, dislodgement or extravasation.

Newer platforms place more emphasis on contoured securement devices, extension-set compatibility and fewer connection steps. Products that combine insertion, securement and infusion access into a single workflow are likely to gain preference in standardized hospital purchasing.

Broader Needle-Length Portfolios

A limited needle range can create uncertainty in pediatric patients, very small adults and patients with substantial soft tissue above the insertion site.

BD now markets five needle lengths across its IO platform. Teleflex offers different needle sizes for patient and anatomical requirements. This shows how competition is shifting toward body-size coverage rather than a one-size-fits-all approach.

Future R&D will focus on penetration-depth control, clearer tissue-depth assessment and easier needle selection. Color coding and improved labeling may also reduce selection errors.

Battery-Free Systems for Austere Environments

Manual devices continue to matter. They are not simply lower-cost substitutes for powered systems.

Battery-independent operation is useful in military medicine, disaster zones, remote rescue and resource-limited settings. SAM Medical’s manual driver creates rotational needle movement through repeated trigger activation. The design combines controlled insertion with independence from batteries or chargers.

This product category is likely to remain distinct. Powered systems will lead developed hospital markets, while manual systems retain strategic value in mobile and austere care.

Training Is Becoming Part of the Product Offering

IO access is not used every day by every clinician. Skills can decline when procedures are infrequent. This makes simulation, refresher training and competency assessment important parts of the commercial model.

SAM Medical offers dedicated training drivers, practice needles and simulated anatomical models. Teleflex also positions education as a core support element for emergency-medicine adoption.

Suppliers that provide training infrastructure can improve account retention. They can also lower resistance from hospitals concerned about inconsistent insertion technique.

Clinical Evidence Will Refine Rather Than Eliminate IO Use

Recent evidence has introduced more caution around the routine use of IO as the first vascular-access route in adult out-of-hospital cardiac arrest. The American Heart Association’s 2025 guidance recommends IV access first when feasible. IO remains reasonable when IV attempts fail or cannot be performed.

This may change product messaging. Manufacturers will need to emphasize difficult vascular access, treatment continuity and specific clinical conditions rather than implying that IO is superior to IV in every resuscitation.

Expert view: The market’s next growth phase will depend less on replacing IV access and more on defining exactly where IO removes dangerous treatment delays. Suppliers with strong clinical education will be better positioned than those selling the device as a universal first-line solution.

Implantable IO Access Is an Early-Stage Adjacency

Most commercial IO products are temporary emergency-access devices. An emerging R&D direction involves implantable intraosseous access for longer-term drug delivery.

In March 2024, PAVmed and Hatch Medical formed a joint venture to advance PortIO, an implantable vascular-access device placed into bone. The technology had completed an early first-in-human study but remained in development. It is not included in the core market estimate because its use case and regulatory path differ from temporary emergency IO systems.

The concept is still strategically relevant. If implantable IO access proves clinically and commercially viable, it could create a separate category serving patients who require repeated vascular access.

Recent Competitive and Innovation Events

The acquisition of SAM Medical by Tri-Tech Forensics is particularly relevant to tactical and pre-hospital channels. Tri-Tech already supplies emergency and first-responder products. Adding SAM’s IO system creates bundling opportunities across trauma kits, circulatory management and military medicine.

Commercially, Teleflex retains a strong position through its installed base and broad emergency-medicine portfolio. BD’s enhanced platform adds credible competition in powered devices. SAM Medical remains differentiated through manual operation. Competition through 2035 will therefore center on workflow, safety and account conversion rather than radical changes to the underlying access route.

Expert view: By 2035, the Intraosseous Infusion Devices Market will look more like a recurring procedural-systems business. Disposable needles, integrated trays, stabilizers and training services will create more value than the driver alone. The winning supplier won’t necessarily have the fastest drill. It will have the system that is available, complete and familiar when the emergency begins.

Competitive Intelligence and Benchmarking

The Intraosseous Infusion Devices Market has a concentrated competitive structure. A small group of suppliers controls the powered, manual and spring-assisted device categories. The strongest companies do more than manufacture needles. They provide insertion systems, securement products, training kits, clinical education and distribution support.

Competition is now shifting from basic insertion speed to system readiness. Hospitals and EMS agencies want assurance that the device is charged, correctly sized, easy to secure and available with every component required for the procedure.

Competitive Benchmarking Matrix

Teleflex

Teleflex holds the strongest competitive position in conventional intraosseous access. Its portfolio covers powered insertion, disposable needle sets, securement, extension components, sterile procedure configurations and a separate system designed for sternal access.

The company’s advantage comes from its installed base. Hospitals and ambulance services that already own reusable drivers generate recurring demand for compatible needles and accessories. Switching suppliers can require new protocols, purchasing approvals, simulation exercises and staff retraining.

Teleflex also benefits from a broader emergency-medicine portfolio. This supports bundled selling to trauma centers, EMS organizations, military medical units and public procurement agencies. Its 2025 annual report confirms that intraosseous systems remain part of the company’s hospital and pre-hospital vascular-access portfolio.

The company announced a wider portfolio restructuring during 2025–2026. Its vascular-access and emergency-medicine businesses remain among its core strategic operations. This should preserve investment around high-acuity products, although management changes and restructuring can temporarily redirect commercial attention.

Analyst view: Teleflex’s most defensible asset is not the powered driver itself. It is the installed ecosystem of needles, training, protocols and clinician familiarity surrounding the device.

BD

BD is the most credible large-scale challenger to Teleflex. The company competes with both powered and manually operated configurations. Its platform includes several needle lengths, securement components, extension connectivity and training support.

Its updated powered driver uses a rechargeable battery and a visible charge indicator. The disposable needle design also incorporates passive needle-tip protection. These features address two important procurement concerns: whether a stored device will function during an emergency and whether the exposed stylet creates avoidable needlestick risk.

BD can use its existing relationships with vascular-access teams, hospital purchasing groups and clinical educators to support adoption. This gives the company a stronger account-conversion platform than a small specialized IO manufacturer.

The main challenge is switching inertia. An emergency department that has standardized its trays, training and protocols around an existing system may require a clear clinical or economic benefit before changing suppliers.

SAM Medical / Tri-Tech Forensics

SAM Medical, now owned by Tri-Tech Forensics, competes through a reusable manually powered insertion platform. The clinician activates a mechanical driver to produce controlled rotational movement. It does not depend on a battery or charging infrastructure.

This creates a differentiated position in military medicine, disaster response, rural EMS and mobile care. The company also supplies training drivers, practice needles and simulated anatomy products. That matters because IO competence can decline when individual clinicians perform few procedures.

Tri-Tech Forensics acquired SAM Medical in May 2024, adding intraosseous access to a wider portfolio of trauma and emergency-response products. The transaction provides cross-selling opportunities through tactical, law-enforcement, defense and first-responder distribution channels.

Its competitive weakness is scale. It does not have the same hospital contracting reach as Teleflex or BD. Growth will therefore depend on distributor performance, military procurement and targeted conversions rather than broad hospital-system penetration.

Safeguard Medical / PerSys Medical

Safeguard Medical competes through the automatic, single-use category developed by PerSys Medical. Its portfolio covers adult, pediatric and infant use. The adult and pediatric systems use spring-assisted insertion, while the infant configuration uses a controlled manual approach designed for very small patients.

The commercial proposition is simple: no reusable driver, no battery, no charging and no separate capital purchase. The devices arrive packaged for immediate use. Ruggedized formats are also available for military and extreme-environment applications.

This model can perform well in ambulances, emergency bags, remote clinics and disaster reserves. It also lowers the barrier for customers that need IO capability but cannot justify purchasing and maintaining multiple powered drivers.

The trade-off is procedural cost. A fully disposable automatic unit generally carries a higher per-use device cost than a replacement needle used with an existing reusable driver. Large hospitals with consistent procedure volume may therefore favor reusable platforms.

ZIEN Medical Technologies

ZIEN Medical Technologies is an emerging competitor in manually powered IO access. Its system combines a reusable mechanical rotary driver with disposable needle assemblies. The needle may also be inserted manually without the driver.

The US FDA granted 510(k) clearance in July 2024. The clearance covers adult and pediatric access through the proximal tibia, distal tibia and humeral head, with an additional pediatric distal-femur indication. The system is intended for hospital, pre-hospital, acute-care and military environments.

The platform could appeal to buyers seeking controlled rotary insertion without battery dependence. However, regulatory clearance alone does not create market scale. ZIEN Medical Technologies will need distributors, clinical reference sites, training infrastructure and consistent manufacturing capacity to challenge established suppliers.

PAVmed / PortIO Inc.

PAVmed represents a longer-term technology adjacency rather than a direct competitor in temporary emergency access. Its development-stage platform is designed to remain beneath the skin and provide longer-duration intraosseous access.

In April 2026, the company appointed dedicated leadership to PortIO Inc. as part of a relaunched medical-device portfolio. A subsequent May 2026 update confirmed that development activity was progressing.

The concept could serve patients with poor venous access or repeated infusion requirements. However, it should not be included in the core temporary IO device forecast until the product completes its clinical and regulatory pathway.

The opportunity is substantial but uncertain. Long-term implantable IO access requires different clinical evidence, reimbursement logic, insertion workflows and risk management than short-duration emergency devices.

Competitive Positioning Outlook

Through 2035, the market will likely remain divided into four strategic positions:

• Installed-platform leadership, led by Teleflex.
• Large-company account conversion, led by BD.
• Battery-independent mechanical systems, represented by SAM Medical and ZIEN Medical Technologies.
• Single-use automatic systems, led by Safeguard Medical / PerSys Medical.

The market is unlikely to consolidate around one insertion mechanism. Hospitals may prefer powered devices. Military and remote-care users may favor manual systems. Low-frequency users may select fully disposable products because they avoid driver maintenance.

Regional Landscape and Adoption Outlook

Regional adoption varies widely. IO devices may be clinically recognized across most major healthcare systems, but commercial demand depends on local resuscitation protocols, ambulance capabilities, staff training, device registration and procurement budgets.

Regional Comparison

United States

The United States remains the largest national market. It has a large network of hospital emergency departments, trauma centers, fire-based EMS agencies, private ambulance operators, air-medical services and military medical units.

The country has more than 18,000 local EMS agencies responding to emergency calls. This creates a wide installed base for compact vascular-access equipment, although procurement remains decentralized across states, municipalities and health systems.

The American Heart Association’s 2025 guidance recommends attempting IV access first during adult cardiac arrest. IO access remains reasonable when IV access is unsuccessful or not feasible. This supports continuing demand but may moderate usage in agencies that previously treated IO as an equivalent first option.

Commercial opportunities will come from:

• Replacing older reusable drivers.
• Converting hospital systems between competing platforms.
• Expanding procedure-ready kits in code carts and operating rooms.
• Improving pediatric readiness in EMS agencies.
• Supplying securement, needles and other recurring consumables.

FDA clearance and established predicate devices make the US regulatory pathway clearer than in some emerging markets. However, new products generally need to demonstrate substantial equivalence through the 510(k) process before commercialization.

Europe

European adoption is strongest in Germany, the United Kingdom, France, the Netherlands and the Nordic countries. These markets have developed ambulance systems, advanced resuscitation training and established emergency-care protocols.

The European Resuscitation Council’s 2025 guidance continues to recognize IO as an alternative route for emergency medications and fluids. Actual implementation remains local because each country applies the recommendations through its own healthcare laws, clinical protocols and procurement structures.

The United Kingdom is an important reference market because national resuscitation equipment standards call for IO devices and needles suitable for neonates, children and adults to be available in acute-care settings.

Growth will be supported by equipment replacement and greater standardization of difficult-access protocols. Spain, Poland, the Czech Republic and selected Southern and Eastern European countries offer above-average expansion potential as emergency-care systems modernize.

Regulation is a more demanding factor. Devices sold in the European Union must comply with the Medical Device Regulation. Manufacturer documentation, notified-body capacity, post-market surveillance and EUDAMED requirements can raise commercialization costs. Mandatory use of the first EUDAMED modules begins from May 28, 2026.

Europe also benefits from public healthcare and resilience funding. The EU4Health 2021–2027 program supports stronger and more accessible health systems, although IO equipment purchasing decisions remain mainly national, regional or hospital based.

China

China offers one of the largest long-term volume opportunities. Adoption is currently concentrated in major tertiary hospitals, advanced emergency departments, military facilities and EMS systems in cities such as Beijing, Shanghai, Guangzhou, Shenzhen and Chengdu.

Demand should expand as emergency-care training moves beyond leading urban hospitals. Pediatric emergency departments, trauma centers and critical-care units represent the most attractive initial targets.

Imported manufacturers face three commercial requirements:

• NMPA product registration.
• A domestic legal agent.
• Access to provincial or hospital tendering channels.

China’s device registration provisions require overseas applicants to designate a domestic enterprise to act as their agent. Manufacturers must also maintain an appropriate quality-management system.

The country could grow faster than the global average. Still, international suppliers will face pricing pressure and possible competition from locally produced mechanical devices. Local assembly or licensing partnerships may become more important if public procurement gives greater weight to domestic production.

Analyst view: China’s opportunity is large, but it won’t be captured through registration alone. Suppliers need provincial distributors, training programs and hospital reference accounts capable of influencing clinical protocols.

India

India is expected to record strong percentage growth from a relatively small installed base. Current adoption is concentrated in private hospital chains, metropolitan trauma centers, air-ambulance providers, military services and better-equipped state ambulance networks.

The country is expanding and standardizing emergency transport infrastructure. Updated National Ambulance Service guidance issued in 2026 defines ambulance categories and operating requirements across emergency, referral and patient-transport services.

The best near-term opportunities are likely to be found in:

• Delhi NCR
• Mumbai
• Bengaluru
• Hyderabad
• Chennai
• Pune
• Ahmedabad
• Major defense and public medical institutions

Powered systems will gain traction in premium hospitals. Manual and spring-assisted systems may be more suitable for district ambulances, disaster-response teams and organizations that cannot reliably manage reusable batteries.

India regulates medical devices through the Medical Devices Rules, 2017. Importers require the applicable CDSCO authorization, and all regulated devices must meet licensing and quality requirements.

Public health-infrastructure spending can indirectly support the market. PM-ABHIM includes investments in emergency operations, critical-care capacity and frontline health-system preparedness. However, budget allocation for specialized IO devices will continue to compete with basic emergency equipment and essential medicines.

Price sensitivity is the largest restraint. Suppliers may need smaller procedure packs, reusable manual drivers, local training partnerships and tiered pricing to expand beyond premium institutions.

Japan

Japan has advanced hospitals and well-developed emergency transport systems. Adoption is expected to remain steady rather than rapid. IO access is mainly used as a backup method in cardiac arrest, pediatric emergencies, severe shock and difficult vascular-access cases.

Tokyo, Osaka, Kanagawa, Aichi and other large urban prefectures represent the main commercial centers. Purchasing decisions tend to favor devices with strong safety documentation, reliable local service and Japanese-language training.

Medical devices are regulated jointly by the Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency. Foreign suppliers require a structured local regulatory and distribution strategy. PMDA submissions and associated documentation are generally handled in Japanese.

Japan is a high-quality but conservative market. Hospitals may keep established systems for long periods. New suppliers will need evidence of improved safety, battery reliability or procedural control to justify conversion.

South Korea

South Korea offers a smaller but faster-moving opportunity. Adoption is centered on tertiary hospitals in Seoul, Busan, Incheon, Daegu and Daejeon, along with public emergency-response services.

The market benefits from a concentrated hospital system, strong emergency-medicine capabilities and comparatively rapid adoption of modern medical technologies. This can make national training and distributor-led conversion more efficient than in geographically larger markets.

MFDS requires technical documentation for certification or approval. Lower-risk devices may be certified through designated bodies, while higher-risk and new medical devices can require direct MFDS approval.

The most attractive products will be compact systems with clear battery or readiness indicators, passive needle safety and strong pediatric coverage. Local clinical education remains essential because the addressable procedure volume is limited and concentrated.

Middle East

The Middle East is relevant because of government-funded hospital expansion, military medical demand, trauma exposure and investment in ambulance services.

Saudi Arabia and the United Arab Emirates are the leading commercial markets. Qatar, Kuwait and Israel also support selected demand, although procurement and regulatory pathways differ.

Saudi opportunities are concentrated in:

• Ministry of Health hospitals.
• Military and National Guard medical systems.
• Red Crescent and emergency-response services.
• Major tertiary and trauma hospitals.
• Government tenders linked to healthcare modernization.

Medical devices cannot be traded in Saudi Arabia without the required SFDA registration and marketing authorization. Local authorized representatives and licensed distributors are therefore central to market entry.

The UAE offers a smaller but premium market. Product registration is required for importing and commercializing medical equipment, and government and private hospital networks can act as regional reference accounts.

Across the Middle East, manual and ruggedized systems have additional relevance for military, remote-site and disaster-response use. Premium powered systems will remain concentrated in large urban hospitals.

Recent Developments, Opportunities and Restraints

Recent Developments

The developments show two opposing forces. Device companies continue to invest in better systems. At the same time, clinical guidelines are defining IO more narrowly as a backup when rapid IV access cannot be achieved.

Opportunities and Business Insights

Procedure-Ready Kits and Recurring Consumables

The strongest near-term opportunity is not necessarily another reusable driver. It is a complete sterile configuration containing the needle, extension line, securement product, preparation material and sharps-management components.

These kits increase revenue per procedure. They also solve a real hospital problem by ensuring that every required component is available together.

Emerging EMS and Trauma-Care Markets

China, India, the Middle East, Southeast Asia and parts of Latin America offer expansion potential as ambulance networks and trauma systems improve.

The best product will vary by setting. Premium hospitals may select rechargeable powered systems. Rural EMS and military users may prefer manual or spring-assisted devices that do not depend on batteries.

Training, Simulation and Readiness Services

Training can become a recurring service rather than a one-time product demonstration. Suppliers can provide competency assessments, simulation kits, protocol templates, inventory checks and digital refresher modules.

AI is not yet central to the actual insertion procedure. The more realistic digital opportunity lies in tracking staff competency, device expiration, battery readiness and product location.

Market Restraints

IV-First Clinical Preference

The strongest restraint is the preference for intravenous access when it can be achieved rapidly. Updated evidence does not remove IO from emergency care, but it discourages treating IO as universally equivalent to IV in every adult cardiac arrest.

Higher Cost Per Access Attempt

An IO needle or disposable automatic device costs considerably more than a standard peripheral IV cannula. Hospitals and ambulance services may therefore restrict IO use to failed or impractical IV access.

Low Procedure Frequency and Skill Retention

Many clinicians use IO devices infrequently. This creates a risk of incorrect site selection, poor stabilization, wrong needle sizing or delayed recognition of extravasation. Continuous training raises the total cost of ownership.

Regulatory and Tender Complexity

Manufacturers must manage different registrations, labeling requirements, authorized representatives and tender systems across the United States, Europe, China, India, Japan, South Korea and the Middle East. This favors established suppliers with larger regulatory and distributor networks.

Expert view: Future growth will come from making IO access safer and more dependable within a clearly defined clinical role. The market does not need IO to replace IV therapy. It needs IO to be available immediately when IV therapy fails.